Sector News

Sorin And Cyberonics Announce Designees To Board Of Directors Of Combined Company

June 12, 2015
Life sciences
/PRNewswire/ – Sorin S.p.A.,, a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation, today announced their respective designees to the Board of Directors of the combined company effective at the close of their proposed merger.
 
As previously announced, under the terms of the merger agreement entered into by Cyberonics and Sorin, the Board of Directors of the combined company will be comprised of nine members, four of whom are to be designated by Sorin and four of whom are to be designated by Cyberonics. Dan Moore, Cyberonics’ current Chief Executive Officer, will be the non-executive Chairman of the Board of Directors of the combined company. André-Michel Ballester, Sorin’s Chief Executive Officer, will serve as the combined company’s Chief Executive Officer and a member of its Board of Directors.
 
In addition to Messrs. Moore and Ballester, the Board of Directors will be comprised of the following individuals, who the companies believe have the expertise, breadth of experience and perspective to guide the combined company:
 
  • Rosario Bifulco, Sorin’s current Chairman.
  • Hugh Morrison, Cyberonics’ current Chairman.
  • Alfred J. Novak, a member of Cyberonics’ Audit and Nominating & Governance Committees.
  • Arthur L. Rosenthal, chairman of Cyberonics’ Compensation Committee and a member of its Audit Committee.
  • Massimo Tononi, a member of Sorin’s current Board of Directors.
  • Francesco Bianchi, a former member of Sorin’s Board of Directors.
 
Sorin and Cyberonics have initiated a search for the ninth director of the combined company, to be jointly designated by them.
 
Until the closing of the transaction, the respective companies will continue to operate under their current leadership structures and as two separate companies.  As previously announced, the transaction is expected to be completed by the end of the third calendar quarter of 2015 and is subject to approval by Cyberonics’ stockholders, the receipt of required regulatory clearances, and other customary closing conditions.  The cross-border merger of Sorin with and into Sand Holdco PLC (“HoldCo”), the new company that was formed to acquire both Cyberonics and Sorin as part of the proposed merger, was approved by Sorin’s shareholders at its extraordinary shareholders’ meeting held on May 26, 2015.
 
Source: Cyberonics

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach